Emergex, a clinical-stage, privately-held biotechnology company headquartered in Abingdon, UK, with an operating subsidiary in Doylestown, Pennsylvania, USA, is pioneering the development of 100% synthetic T cell-priming immune set-point vaccine candidates that harness and direct the body’s natural... Read more
Queen Mary University
7 followers
Oxford Nanopore Technologies
19 followers
Calico
8 followers
Autolus
7 followers
Vaxcyte
5 followers
Discovery Life Sciences
3 followers
Universal Diagnostics
3 followers
FUJIFILM Diosynth Biotechnologies
33 followers
Edgewise Therapeutics
2 followers
TryHackMe
3 followers
Entos
1 follower
Wintermute
19 followers